Compounds for treating dengue virus infections and other infections

A method of inhibiting the entry of a virus into a cell comprising contacting the cell with an effective amount of a compound of Formula (I) or (II):

• or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
• Ring A is optionally substituted phenyl or optionally substituted 6,5-fused bicyclic heteroaryl;
• Z is selected from the group consisting of —O—, —NRN—, —S—, —C(RC)2—, —OC(═O)—, —C(═O)O—, —C(═O)NRN—, —NRNC(═O)—, —NRNS(═O)2—, and —S(═O)2NRN—;
• Y is selected from the group consisting of —O—, —NRN—, —S—, and —C(RC)2—;
• X1 is hydrogen, halogen, or optionally substituted alkyl;
• X2 is hydrogen, halogen, or optionally substituted alkyl;
• G1 is C—R3 or N;
• each instance of R2 and R3 is independently hydrogen, halogen, —CN, —NO2, —N3, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted acyl, —ORO, —N(RN)2, or —SRS;
• m is 0, 1, 2, or 3;
• n is 0, 1, 2, 3, or 4;
• each instance of RC is independently hydrogen, halogen, —CN, optionally substituted alkyl, or optionally substituted acyl;
• each instance of RO is independently hydrogen, optionally substituted alkyl, optionally substitute acyl, or an oxygen protecting group;
• each instance of RN is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group, optionally wherein two RN bonded to the same nitrogen atom are joined together with the intervening atoms to form optionally substituted heterocyclyl or optionally substituted heteroaryl;
• and
• each instance of RS is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a sulfur protecting group.

A method of inhibiting an envelope glycoprotein of a virus comprising contacting the virus with an effective amount of a compound of Formula (I) or (II):

• or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
• Ring A is optionally substituted phenyl or optionally substituted 6,5-fused bicyclic heteroaryl;
• Z is selected from the group consisting of —O—, —NRN—, —S—, —C(RC)2—, —OC(═O)—, —C(═O)O—, —C(═O)NRN—, —NRNC(═O)—, —NRNS(═O)2—, and —S(═O)2NRN—;
• Y is selected from the group consisting of —O—, —NRN—, —S—, and —C(RC)2—;
• X1 is hydrogen, halogen, or optionally substituted alkyl;
• X2 is hydrogen, halogen, or optionally substituted alkyl;
• G1 is C—R3 or N;
• each instance of R2 and R3 is independently hydrogen, halogen, —CN, —NO2, —N3, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted acyl, —ORO, —N(RN)2, or —SRS;
• m is 0, 1, 2, or 3;
• n is 0, 1, 2, 3, or 4;
• each instance of RC is independently hydrogen, halogen, —CN, optionally substituted alkyl, or optionally substituted acyl;
• each instance of RO is independently hydrogen, optionally substituted alkyl, optionally substitute acyl, or an oxygen protecting group;
• each instance of RN is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group, optionally wherein two RN bonded to the same nitrogen atom are joined together with the intervening atoms to form optionally substituted heterocyclyl or optionally substituted heteroaryl;
• and
• each instance of RS is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a sulfur protecting group.

A compound of Formula (III):

• or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
• R1 is —ORO or —N(RN)2;
• Z is selected from the group consisting of —O—, —NRN—, —S—, —C(RC)2—, —OC(═O)—, —C(═O)O—, —C(═O)NRN—, —NRNC(═O)—, —NRNS(═O)2—, and —S(═O)2NRN—;
• Y is selected from the group consisting of —O—, —NRN—, —S—, and —C(RC)2—;
• each instance of R2 and R3 is independently hydrogen, halogen, —CN, —NO2, —N3, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted acyl, —ORO, —N(RN)2, or —SRS;
• m is 0, 1, 2, or 3;
• n is 0, 1, 2, 3, or 4;
• s is 1, 2, or 3;
• each instance of RC is independently hydrogen, halogen, —CN, optionally substituted alkyl, or optionally substituted acyl;
• each instance of RO is independently hydrogen, optionally substituted alkyl, optionally substitute acyl, or an oxygen protecting group;
• each instance of RN is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group, optionally wherein two RN bonded to the same nitrogen atom are joined together with the intervening atoms to form optionally substituted heterocyclyl or optionally substituted heteroaryl;
• and
• each instance of RS is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a sulfur protecting group.

A compound of Formula (IV):

• or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, wherein:
• G1 is C—R4 or N.
• Z is selected from the group consisting of —O—, —NRN—, —S—, —C(RC)2—, —OC(═O)—, —C(═O)O—, —C(═O)NRN—, —NRNC(═O)—, —NRNS(═O)2—, and —S(═O)2NRN—;
• Y is selected from the group consisting of —O—, —NRN—, —S—, and —C(RC)2—;
• each instance of R2 and R3 is independently hydrogen, halogen, —CN, —NO2, —N3, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted acyl, —ORO, —N(RN)2, or —SRS;
• m is 0, 1, 2, or 3;
• n is 0, 1, 2, 3, or 4;
• r is 0, 1, 2, 3, 4, or 5;
• each instance of RC is independently hydrogen, halogen, —CN, optionally substituted alkyl, or optionally substituted acyl;
• each instance of RO is independently hydrogen, optionally substituted alkyl, optionally substitute acyl, or an oxygen protecting group;
• each instance of RN is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group, optionally wherein two RN bonded to the same nitrogen atom are joined together with the intervening atoms to form optionally substituted heterocyclyl or optionally substituted heteroaryl;
• each instance of RS is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a sulfur protecting group;
• and
• each instance of R4 is independently hydrogen, halogen, —CN, —NO2, —N3, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted acyl, —ORO, —N(RN)2, or —SRS.